Literature DB >> 1654333

Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants.

W K Sonnenburg1, P J Mullaney, J A Beavo.   

Abstract

We have cloned a 4.2-kilobase pair (kb) cDNA that encodes the cyclic GMP-stimulated phosphodiesterase (cGS PDE) from a bovine adrenal cortex library. The 921-residue polypeptide deduced from the cDNA nucleotide sequence is nearly identical with the complete amino acid sequence of the cGS PDE purified from a soluble bovine heart extract. Moreover, PPD-S49 cells transfected with the cGS PDE cDNA express a soluble cAMP hydrolytic activity that is enhanced by cGMP. Total RNA isolated from several bovine tissues were screened for cGS PDE transcript by Northern blot analysis. The cGS PDE cDNA appears to hybridize to a single 4.5-4.6-kb mRNA species. Although the cGS PDE mRNA is most abundant in the adrenal cortex, it is also concentrated in the adrenal medulla and heart and in anatomically distinct regions of the brain and kidney. A mRNA species encoding a putative variant cGS PDE isoform was detected by RNase protection. Total RNA isolated from adrenal cortex, adrenal medulla, liver, kidney, trachea, lung, spleen, and T-lymphocytes completely protected a 452-base riboprobe encoding 100 residues of the adrenal cortex cGS PDE amino terminus. In contrast, RNAs isolated from brain (cerebral cortex, hippocampus, and basal ganglia) protected only 268 bases of this riboprobe. The RNase protection pattern of this same probe using heart RNA showed major bands at both 268 and 452 bases, suggesting that two different cGS PDE mRNA species are expressed. These results indicate that the cGS PDE is widely expressed in a variety of tissues. Moreover, these studies suggest that at least one different cGS PDE isoform having a structurally distinct amino-terminal domain is expressed in brain and heart.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654333

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5' guanosine monophosphate accumulation in retinal pigment epithelium cells.

Authors:  R M H Diederen; E C La Heij; M Markerink-van Ittersum; A Kijlstra; F Hendrikse; J de Vente
Journal:  Br J Ophthalmol       Date:  2006-08-30       Impact factor: 4.638

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

3.  A phosphodiesterase 2A isoform localized to mitochondria regulates respiration.

Authors:  Rebeca Acin-Perez; Michael Russwurm; Kathrin Günnewig; Melanie Gertz; Georg Zoidl; Lavoisier Ramos; Jochen Buck; Lonny R Levin; Joachim Rassow; Giovanni Manfredi; Clemens Steegborn
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

Review 4.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

Review 5.  Phosphodiesterases and adrenal Cushing in mice and humans.

Authors:  E Szarek; C A Stratakis
Journal:  Horm Metab Res       Date:  2014-09-18       Impact factor: 2.936

6.  Isolation and characterization of multiple adenylate cyclase genes from the cyanobacterium Anabaena sp. strain PCC 7120.

Authors:  M Katayama; M Ohmori
Journal:  J Bacteriol       Date:  1997-06       Impact factor: 3.490

Review 7.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

8.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

9.  The distribution of phosphodiesterase 2A in the rat brain.

Authors:  D T Stephenson; T M Coskran; M P Kelly; R J Kleiman; D Morton; S M O'Neill; C J Schmidt; R J Weinberg; F S Menniti
Journal:  Neuroscience       Date:  2012-09-19       Impact factor: 3.590

10.  Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase.

Authors:  R Pillai; K Kytle; A Reyes; J Colicelli
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.